Insight 2811 Inc’s AbbVie ABBV Stock Holding History

Insight 2811 Inc’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$557K	Buy	2,212 +38	+2%	+$8.18K	0.22%	57
2026 Q1	$473K	Buy	2,174 +26	+1%	+$5.77K	0.2%	59
2025 Q4	$491K	Buy	2,148 +1	+0%	+$228	0.22%	53
2025 Q3	$497K	Buy	2,147 +8	+0.4%	+$1.63K	0.22%	51
2025 Q2	$397K	Sell	2,139 -8	-0.4%	-$1.49K	0.19%	59
2025 Q1	$450K	Sell	2,147 -32	-1%	-$6.22K	0.23%	50
2024 Q4	$387K	Buy	2,179 +4	+0.2%	+$735	0.2%	58
2024 Q3	$430K	Hold	2,175	–	–	0.21%	51
2024 Q2	$373K	Sell	2,175 -1,600	-42%	-$265K	0.19%	56
2024 Q1	$688K	Hold	3,775	–	–	0.35%	35
2023 Q4	$585K	Sell	3,775 -24	-0.6%	-$3.5K	0.32%	35
2023 Q3	$566K	Sell	3,799 -289	-7%	-$42.4K	0.32%	36
2023 Q2	$551K	Buy	4,088 +1,932	+90%	+$283K	0.3%	39
2023 Q1	$344K	Sell	2,156 -15	-0.7%	-$2.29K	0.21%	58
2022 Q4	$351K	Buy	+2,171	New	+$333K	0.22%	59
2022 Q3	–	Sell	-1,323	Closed	-$203K	–	83
2022 Q2	$203K	Buy	1,323 +66	+5%	+$10.1K	0.13%	78
2022 Q1	$204K	Buy	+1,257	New	+$183K	0.12%	85
2013 Q3	–	Sell	-500	Closed	-$21K	–	96
2013 Q2	$21K	Buy	+500	New	+$21.9K	0.01%	170

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Insight 2811 Inc's ABBV Position: Q2 2026 in Review

Insight 2811 Inc increased its AbbVie (ABBV) stake by 1.7% in Q2 2026, buying an estimated $8.18K and bringing the position to 2,212 shares worth $557K. The position accounts for 0.22% of the portfolio, ranked #57.

Insight 2811 Inc first reported a position in ABBV in Q2 2013 and has held it in 18 quarters since. The position peaked at $688K in Q1 2024. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Insight 2811 Inc held 2,212 shares of AbbVie worth $557K as of Q2 2026.
Insight 2811 Inc bought 38 AbbVie shares in Q2 2026, an estimated $8.18K.
AbbVie made up 0.22% of Insight 2811 Inc's portfolio in Q2 2026, its #57 holding.
Insight 2811 Inc first reported a position in AbbVie in Q2 2013 and has held it in 18 quarters since.
Insight 2811 Inc's AbbVie position peaked at $688K in Q1 2024.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Insight 2811 Inc's 13F filing for Q2 2026, filed 11 Aug 2026.